Guangzhou LBP Medicine Science & Technology Co Ltd - Asset Resilience Ratio
Guangzhou LBP Medicine Science & Technology Co Ltd (688393) has an Asset Resilience Ratio of 18.18% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Guangzhou LBP Medicine Science & Technol debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Guangzhou LBP Medicine Science & Technology Co Ltd's Asset Resilience Ratio has changed over time. See 688393 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Guangzhou LBP Medicine Science & Technology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guangzhou LBP Medicine Science & Technol market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥238.51 Million | 18.18% |
| Total Liquid Assets | CN¥238.51 Million | 18.18% |
Asset Resilience Insights
- Good Liquidity Position: Guangzhou LBP Medicine Science & Technology Co Ltd maintains a healthy 18.18% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Guangzhou LBP Medicine Science & Technology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangzhou LBP Medicine Science & Technology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
SKAN Group AG
SW:SKAN |
Medical Instruments & Supplies | 13.88% |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151 |
Medical Instruments & Supplies | 26.12% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 6.36% |
|
Spineway
PA:ALSPW |
Medical Instruments & Supplies | -0.24% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 4.42% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 51.82% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
Annual Asset Resilience Ratio for Guangzhou LBP Medicine Science & Technology Co Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Guangzhou LBP Medicine Science & Technology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.06% | CN¥55.33 Million ≈ $8.10 Million |
CN¥1.36 Billion ≈ $199.41 Million |
+0.31pp |
| 2023-12-31 | 3.75% | CN¥52.56 Million ≈ $7.69 Million |
CN¥1.40 Billion ≈ $204.85 Million |
-8.85pp |
| 2022-12-31 | 12.60% | CN¥175.54 Million ≈ $25.69 Million |
CN¥1.39 Billion ≈ $203.81 Million |
-18.11pp |
| 2021-12-31 | 30.71% | CN¥419.42 Million ≈ $61.37 Million |
CN¥1.37 Billion ≈ $199.84 Million |
+14.42pp |
| 2020-12-31 | 16.29% | CN¥210.46 Million ≈ $30.80 Million |
CN¥1.29 Billion ≈ $189.10 Million |
+0.51pp |
| 2019-12-31 | 15.78% | CN¥84.88 Million ≈ $12.42 Million |
CN¥537.96 Million ≈ $78.72 Million |
+15.63pp |
| 2013-12-31 | 0.15% | CN¥376.60K ≈ $55.11K |
CN¥257.13 Million ≈ $37.63 Million |
-4.16pp |
| 2012-12-31 | 4.31% | CN¥8.27 Million ≈ $1.21 Million |
CN¥191.92 Million ≈ $28.08 Million |
+3.87pp |
| 2011-12-31 | 0.43% | CN¥484.40K ≈ $70.88K |
CN¥111.40 Million ≈ $16.30 Million |
-- |
About Guangzhou LBP Medicine Science & Technology Co Ltd
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase… Read more